<DOC>
	<DOCNO>NCT00532350</DOCNO>
	<brief_summary>This study ass safety tolerability QAT370 compare tiotropium patient COPD .</brief_summary>
	<brief_title>Safety Tolerability QAT370 Compared Tiotropium Patients With Chronic Obstructive Pulmonary Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Patients 40 80 year age control COPD . Women must surgically sterilize postmenopausal . Additional birth control postmenopausal information available time enrollment . Body mass index ( BMI ) must within range 18 32 kg/m2 Participation interventional clinical investigation 4 week study start Blood loss donation 400 mL within 2 month study start Significant illness ( respiratory ) within 2 week study start Past medical personal close family history clinically significant ECG abnormalities Any medical condition may interfere exercise testing may make spirometry unsafe A known hypersensitivity drug . History immunocompromise , include positive HIV test result . History drug alcohol abuse within 12 month study start Any condition may compromise patient safety</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>COPD</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>plethysmography</keyword>
	<keyword>cycle ergometry</keyword>
	<keyword>exercise test</keyword>
	<keyword>spirometry</keyword>
</DOC>